AZACITIDINE (AZACITIDINE FOR)
AZACITIDINE (AZACITIDINE FOR) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: AZACITIDINE; Generic name: AZACITIDINE FOR; Drug class: Nucleoside Metabolic Inhibitor [EPC].
| Brand name | AZACITIDINE |
|---|---|
| Generic name | AZACITIDINE FOR |
| Drug class | Nucleoside Metabolic Inhibitor [EPC] |
| Manufacturer | Pilnova Pharma Inc |
| Used for | 1 INDICATIONS AND USAGE Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of: Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1.1 ) 1.1 Myelodysplastic Syndromes (MDS) Azacitidine for injection is indicated for treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome subt |
| Dosage | 2 DOSAGE AND ADMINISTRATION Do not substitute Azacitidine for injection for oral azacitidine. The indications and dosing regimen for Azacitidine for injection differ from that of oral azacitidine ( 2.1 , 5.1 ). MDS: The recommended starting dosage for the first treatment cycle, for all patients regardless of baseline hematology values, is Azacitidine for injection 75 mg/m 2 daily for 7 days to be administered by subcutaneous injection or intravenous infusion. See full prescribing information for |
| Active ingredient(s) | AZACITIDINE |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0095c67b-42f3-47e6-92db-f77843727bca |